Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Software Development

14 Feb 2008 07:01

Angle PLC14 February 2008 For Immediate Release 14 February 2008 ANGLE plc Software Development Kit Launched by Geomerics ANGLE plc is pleased to announce that its venture company Geomerics hascompleted its Software Development Kit (SDK) for Enlighten, the revolutionaryradiosity lighting engine for PLAYSTATION(R)3, the Xbox 360(TM) entertainmentsystem from Microsoft and PC. Enlighten's SDK comprises a modular toolkit withan emphasis on easy integration into existing development frameworks. It alsoboasts intuitive operation designed with artists in mind and full support forindustry standard packages such as 3D Studio Max and Maya for maximumoperability. Enlighten's radiosity solution represents a generational step in videogamegraphics technology, surpassing all currently popular lighting techniques.Radiosity is the ability to model light as it bounces from surfaces and it iskey to generating high quality visual images. Current technologies forgenerating radiosity lighting involve either pre-computing it in advance, orfaking it with multiple hidden lights. These methods are typically inflexible,time-consuming and often generate poor results. Enlighten computes full multiple-bounce radiosity at runtime, giving developersthe quality of pre-computed lighting without the pre-compute. In-game lightingcan also be fully dynamic, giving designers a powerful new tool with hugepotential for enhancing the atmosphere and mood of any scene. Additionally,Enlighten's instantaneous feedback means that artists are freed up to experimentwith light, shadow and colour in dramatic new ways - just as if they were usingreal lights on a studio set. Gary Lewis, CEO, Geomerics comments: "We are delighted to be announcing the launch of the Enlighten SDK. With our SDKcompleted, we are looking forward to seeing Enlighten gaining the support itdeserves within the games industry. We are certain that once developers gettheir hands on the SDK and experiment with it for themselves, they will see thetrue power and versatility of Enlighten and the huge potential it has forrevolutionising the look of videogames for years to come." Geomerics will be at Expo Suite 561 throughout GDC Expo 2008, which runs from20th to the 22nd February. To book a meeting please contact: info@geomerics.com Enlighten is available for licensing for PC, Xbox 360 and Playstation 3. Formore information please contact: sales@geomerics.com Enquiries: ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveIan Griffiths, Finance Director Buchanan Communications 0207 466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Angle plc Founded in 1994, ANGLE is an international venture management company focusingon the commercialisation of technology and the development of technology-basedindustry. ANGLE creates, develops and advises technology businesses on its ownbehalf and for its clients. ANGLE has a 48% equity holding in Geomerics Ltd.ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com Geomerics Ltd Geomerics is an innovation-led company specialising in graphics software for thegames industry and beyond. It is built on a combination of advanced in-house IP,a remarkable research team, and strong management experience. The company'sfirst product is Enlighten. Enlighten radically transforms the way that lightingis handled in computer games. Instead of pre-baking the effects of globalillumination into the scene they can now be computed at run time, allowing forfully dynamic lighting. This dramatically enhances realism as well as opening upa new world of creative possibilities for designers and artists. Further information can be found on www.geomerics.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.